Kornimate/medical-research-clean huggingface dataset:
potato consumption and risk of hypertension

Conditions: Hypertension

Summary: government has popularized potatoes as a major staple food in china. potato, a potassium-rich food with high glycemic responses after consumption, exhibits unclear effects on hypertension. in this study, the investigators aimed to examine the association between potato consumption and hypertension risk among chinese people.

potato is considered as a superior crop due to its significant nutritive value and great production yield. china is the largest potato producer with a quarter of world production, followed by india, russia, and usa. the potato production as well as consumption has enhanced in developing countries while continuously declined in developed countries during the last decade. the investigators therefore explored the prospective associations of consumption of total potatoes, sweet potatoes, stir-fried potatoes, and non stir-fried potatoes with the risk of hypertension in general people of the china health and nutrition survey (chns) cohort study from 1989 to 2011. a total of 11,763 participants (≥20 years old) who were free of hypertension at baseline were enrolled from chns cohort study. cox proportional hazards regression models were used to estimate the associations after adjusting for potential confounders. this study provides new evidence on the association of various potato consumption with the incidence of hypertension in china. as urbanization accelerates across the whole domain of china, the tendency of transition to western-style diets and lifestyles appears continuously and steeply growing. more and more potatoes will be consumed as processed potato products including potatoes chips and french fries, which may be a potential risk factor of hypertension occurrence.

Eligibility criteria:
inclusion criteria: * adults aged 20-93 with complete data on diet and follow-up time * adults with no chronic disease history exclusion criteria: * adults aged \< 20 years * identified to be pregnant * previously diagnosed with hypertension, cancers, infarction, apoplexy, and diabetes

Keywords: potato consumption hypertension chns
effectiveness of a childbirth and parenthood preparation education in primigravidas

Conditions: Pregnancy Related; Anxiety

Summary: to investigate the effect of the childbirth and parenthood preparation education on maternal health needs, pregnancy-related anxiety and fetal health anxiety in primigravidas. a total of 148 pregnant women are planned to be included in the study. data will be collected with the 'pregnant identification form', 'maternal health needs scale', 'pregnancy-related anxiety scale-revision 2' and 'fetal health anxiety inventory. the "childbirth and parenthood preparation education" program will be applied to the experimental group for a period of four weeks (a month (each week, once a week in total four sessions)). it is thought that the results of the research will contribute to the welfare of pregnant women by reducing maternal health needs, pregnancy-related anxiety and fetal health anxiety levels.

to investigate the effect of the childbirth and parenthood preparation education on maternal health needs, pregnancy-related anxiety and fetal health anxiety in primigravidas. a total of 148 pregnant women are planned to be included in the study. data will be collected with the 'pregnant identification form', 'maternal health needs scale', 'pregnancy-related anxiety scale-revision 2' and 'fetal health anxiety inventory. the "childbirth and parenthood preparation education" program will be applied to the experimental group for a period of four weeks (a month (each week, once a week in total four sessions)). within the scope of the "childbirth and parenthood preparation training" program; physiological and psychological changes in the mother during pregnancy, daily life during pregnancy, smoking, alcohol and substance use during pregnancy, exercise during pregnancy, nutrition and nutritional support during pregnancy, pregnancy follow-ups, routine examinations and immunization, common problems during pregnancy and suggestions for solutions, signs of danger during pregnancy and what to do, risky pregnancies, drug and human medicinal product management during pregnancy, labor process, drug-free methods for coping with labor pain, postpartum period and its characteristics, physiological changes in the mother after birth, psychological changes in puerperium, puerperal role and adaptation, postpartum behaviors , care of the newborn in the postpartum period, postpartum contraception methods will be explained. it is thought that the results of the research will contribute to the welfare of pregnant women by reducing maternal health needs, pregnancy-related anxiety and fetal health anxiety levels.

Eligibility criteria:
inclusion criteria: * literate * 18-40 years old * primigravida * those who volunteered to participate in the research * pregnant women who do not have communication and mental difficulties exclusion criteria: * those who do not fill out the entire questionnaire * those with risky pregnancy * pregnant women with a previous history of psychiatric illness

Keywords: maternal health needs fetal health anxiety primiparous women childbirth and parenthood preparation education pregnancy-related anxiety
exploration of the perceptions of women with a history of gestational diabetes from the gonesse hospital catchment area regarding their risk of developing type 2 diabetes.

Conditions: Diabetes Mellitus, Type 2; Diabetes, Gestational

Summary: this study focuses on the patients' perspective and aims to provide explanatory elements regarding the barriers to type 2 diabetes screening among women with a history of gestational diabetes. the main objective is to understand the obstacles and enablers in order to optimize type 2 diabetes screening in women with a history of gestational diabetes.


Eligibility criteria:
inclusion criteria: * women with a history of gestational diabetes * aged between 18 and 45 years * french-speaking * followed up at gonesse hospital exclusion criteria: * under 18 or over 45 years old * non-french-speaking
simethicone: does it improve operative field and postoperative pain?

Conditions: Simethicone

Summary: simethicone is an oral anti-foaming agent that reduces bloating, abdominal discomfort, and abdominal pain by promoting the clearance of excessive gas along the gastrointestinal tract. the investigators objective is to evaluate the efficacy and safety of preoperative oral simethicone for bowel preparation in gynecological laparoscopies.

introduction: simethicone is an oral antifoaming agent that reduces bloating, abdominal discomfort, and abdominal pain by promoting the clearance of excessive gas along the gastrointestinal tract. objective: to evaluate the efficacy and safety of preoperative oral simethicone for bowel preparation in gynecological laparoscopies. methods: 100 infertile women will be scheduled for laparoscopy, patients randomized to receive either simethicone (group i) or placebo tablets (group ii). the primary outcome measure will be the overall exposure of the surgical field and pain scoring. assessment of the overall exposure of the surgical field was done using a five-point scale (poor, sufficient, medium, good, and excellent). visual analog score (vas) will be used for assessment of postoperative pain and verbal analog scoring was used for assessment of patient satisfaction.

Eligibility criteria:
inclusion criteria: * infertile patients * aged 20 - 40 years old * scheduled for laparoscopy exclusion criteria: * women were excluded from the study if patients had one or more of the following: * scar of previous operation, uterine mass, severe endometriosis, suspicion of malignancy, history of allergic reaction to study drugs, psychiatric disorders and patient refusal

Keywords: simethicone laparoscopies pain
a randomized, parallel-group comparison study of topical corticosteroids in dry eye patients with sjögren syndrome

Conditions: Dry Eye Syndromes; Sjögren Syndrome

Summary: the purpose of this study is to evaluate the effectiveness of fluorometholone combined with sodium hyaluronate eye drops in the treatment of sjögren syndrome.


Eligibility criteria:
inclusion criteria: * willing to participate in this clinical study, and signed informed consent * age from 18 to 70 years old,both genders are permitted * diagnosed as the sjögren syndrome * have the symptoms and signs of dry eye disease as below: 1. have at least 2 symptoms such as dryness,foreign body sensation ,eye strain,conjunctival congestion,secretion.the summed up score of symptoms greater than 6. 2. the score of tear-film break up time less than 5 seconds or the score of schirmer test less than 5mm/5min. 3. the score of corneal fluorescein staining greater than 3. exclusion criteria:

Keywords: corticosteroids dry eye sjögren syndrome inflammation treatment
three dose regimen of tranexamic acid in cardiac surgery

Conditions: Hemostasis

Summary: tranexamic acid is thought to be a promising substitute for aprotinin when the latter has seceded in 2007. yet the ideal dosage and dosing regimen of tranexamic acid in cardiopulmonary bypass cardiac surgery in chinese population remains controversial. the current study includes patients receiving valvular replacement and coronary artery bypass surgery. three dosage regimen of tranexamic acid is delivered and blood loss, transfusions and clinical outcomes are recorded.


Eligibility criteria:
inclusion criteria: * rheumatic or recessive valvular disease patients requiring valvular replacement surgery with cardiopulmonary bypass * coronary artery disease patients requiring coronary artery bypass surgery with cardiopulmonary bypass * wrriten consent obtained exclusion criteria: * non-primary cardiac surgery * preoperative liver or renal dysfunction * preoperative coagulation disorder * allergy * pregnancy or lactation * disabled in spirit or law * fatal conditions such as tumour

Keywords: tranexamic acid cardiac surgery procedures hemostasis
brain functional connectivity changes following cognitive rehabilitation in multiple sclerosis: an fmri study

Conditions: MS (Multiple Sclerosis)

Summary: this trial seeks to investigate brain network changes following cognitive rehabilitation in ms patients. the investigators hypothesize that rehabilitation interventions improve connectivity in the brain.novel magnetic resonance imaging technique is performed to investigate changes in brain plasticity.


Eligibility criteria:
inclusion criteria: * definitive ms diagnosis * right handedness * edss 0-4 * no relapse in past 6 weeks * willing to consent and participate in the study exclusion criteria: * pregnancy * left handedness * neurologic or psychiatric disorder other than ms

Keywords: multiple sclerosis mri scans
avatrombopag for platelet recovery post-ucbt in patients with bone marrow failure disease

Conditions: Platelet Recovery After Umbilical Cord Blood Transplantation

Summary: to evaluate the efficacy and safety of avatrombopag for platelet recovery after unrelated cord blood transplantation (ucbt) in patients with bone marrow failure disease

persistent thrombocytopenia is a common complication after umbilical cord blood transplantation (ucbt), which necessitates platelet transfusion and leads to increased transplant-related mortality. this is a single-center, single-arm, phase ii clinical trial aimed at evaluating the efficacy and safety of avatrombopag for platelet recovery after ucbt in patients with bone marrow failure disease (bmfd). the study was conducted in patients diagnosed with bfmd and receiving ucbt. after the subjects signed and informed and qualified, they received avatrombopag treatment from the first day to the 28th day after transplantation. in this study, the cumulative of platelet implantation rate at 28 days after transplantation was used as the main therapeutic index, and 40 patients were planned to be enrolled.

Eligibility criteria:
inclusion criteria: * age ≥12 years old, male or female; * patients diagnosed with bone marrow failure disease including aplastic anemia (aa), fanconi anemia (fa), paroxysmal nocturnal hemoglobinuria (pnh) and undergoing ucbt; * ecog score ≤2; * voluntary participation in this clinical trial, patients fully understand the trial content and sign the informed consent； exclusion criteria: * pregnant or lactating women； * known allergy to avatrombopag; * a history of severe thrombotic events or known risk factors for thrombosis or active thromboembolism requiring anticoagulation; * a history of platelet dysfunction or bleeding prone disease or severe bleeding (requiring more than 2 units of red blood cell infusion or a hematocrit drop of ≥10%) within 7 days prior to screening; * chronic active hepatitis b and c; * repeat or multiple transplantation or multiple organ transplantation; * hiv positive, ebv-dna positive, cmv-dna positive; * have severe infection or complicated with serious heart, liver, lung, kidney, neurological or metabolic diseases; * a serious adverse event (level 4 or 5) as defined by the standard general terminology for adverse events version 4.0 occurred during the pre-treatment period; * participants participate in another clinical study with any exploratory drug or device within 30 days prior to baseline visit; observational studies are allowed; * subjects with cognitive impairment or uncontrolled mental illness; * subjects and/or authorized family members to refuse treatment with avatrombopag; * those who are judged by the researchers as not suitable for inclusion (such as accompanying medical history, which may affect the safety of the subjects or it is estimated that the treatment cannot be adhered to due to financial problems).

Keywords: avatrobopag
measuring molecular residual disease in colorectal cancer after primary surgery and resection of metastases

Conditions: Colorectal Cancer; Residual Disease

Summary: circulating tumour dna (ctdna) is a promising tool when monitoring the residual disease in colorectal cancer (crc). current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy. we will show that the assessment of ctdna is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.


Eligibility criteria:
inclusion criteria: * planned colorectal primary surgery exclusion criteria: * unfit patients with dementia
evaluation of reporting of vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors associated cardiovascular adverse reaction.

Conditions: Cardiac Complication; Vascular Diseases

Summary: antiangiogenics (aas) which are vascular endothelial growth factor (vegf) or vegf receptor (vegfr) inhibitors might have high grade adverse events (aes) on the cardio-vascular system. this study investigates reports of cardio-vascular toxicity with treatment including vegf and vegfr inhibitors using the world health organization (who) database vigibase.

aas have dramatically improved clinical outcomes in multiple cancer types and are increasingly being tested in earlier disease settings and used in combination. however, aes can occur. here the investigators use vigibase (http://www.vigiaccess.org/), the world health organization (who) database of individual safety case reports, to identify cases of cardiovascular adverse drug reaction following treatment with aas.

Eligibility criteria:
inclusion criteria: * case reported in the world health organization (who) database of individual safety case reports to 01/01/2018 * adverse event reported were including the meddra terms: cardiac disorders (soc), vascular disorders (soc), sudden death (pt) * patients treated with antiangiogenics included in the following list: exclusion criteria: * chronology not compatible between the drug and the toxicity

Keywords: vegfr vegf antiangiogenics angiogenesis
development of a risk stratification score for recurrent venous thromboembolism and treatment-related clinically relevant bleeding in patients with cancer-associated thrombosis

Conditions: Cancer-associated Thrombosis

Summary: the objective of this study is to prospectively develop a risk assessment model (ram) that accurately identifies anticoagulated cancer-associated thrombosis (cat) patients at low- and high-risk of recurrent venous thromboembolism (vte) and clinically relevant bleeding within 6 months following the cat diagnosis and to create a biobank of plasma and whole blood samples for further translational research in cancer genetics and hemostasis.

can-catch study is a prospective cohort study to develop a risk assessment model for vte recurrence and clinically relevant bleeding in patients with cat. the study is anticipated to recruit for a period of 2 years with a 3-year completion timeline. the primary objective of this study is to prospectively develop a ram that accurately identifies anticoagulated cat patients at low- and high-risk of cat recurrence and clinically relevant bleeding within 6 months following the cat diagnosis. the secondary objective is to create a biobank of plasma and dna samples at the time of cat diagnosis, linked to the annotated dataset for future translational biomarker research in cancer genetics and hemostasis. at approved sites, participants will donate 4x4.5 ml 3.2% citrate tubes and 3x10 ml ethylenediaminetetraacetic (edta) tubes for blood banking. in addition to the initial enrollment visit, participants that are enrolled will have a follow up at day 90 ± 14 days (3 months) and at day 180 ± 14 days (6 months) from randomization. post enrollment follow-up visits will include assessment and documentation of any major and clinically relevant non-major bleeding (crnmb), investigations for vte, change in cancer treatment regimen, vte risk factors, bleeding risk factors and death. participants who experience an outcome event should continue to be followed

Eligibility criteria:
inclusion criteria: * objectively documented distal and/or proximal dvt of the limb (upper or lower extremity) and/or pe, splanchnic vein thrombosis and/or cerebral sinus vein thrombosis in presence of active cancer of all types * intended treatment of cat for at least 6 months with parenteral or oral anticoagulants at therapeutic dosing. * estimated life expectancy \> 6 months * willingness to give an informed consent * age ≥ 18 years exclusion criteria: * unusual site cat (gonadal vein thrombosis, ovarian vein thrombosis, retinal vein thrombosis) * superficial vein thrombosis * refusal of informed consent \> 72 hrs of anticoagulants * age \< 18 years old
xyrem and brain dopamine in narcolepsy

Conditions: Narcolepsy With Cataplexy; Healthy Controls

Summary: the overall aim of this investigation is to establish whether an action of xyrem® on the brain dopamine system in patients with narcolepsy, and in a comparison control group, might explain part of the anti-narcoleptic effect of the drug. trial objective is to establish, using positron emission tomography (pet), in xyrem®-naïve narcolepsy with cataplexy patients, and in matched controls, whether a single dose of xyrem® causes changes in striatal binding of 11c-raclopride and 11c-dtbz that would suggest altered activity of brain dopamine neurones.


Eligibility criteria:
inclusion criteria: * current diagnosis of narcolepsy with cataplexy or healthy control exclusion criteria: * use of any sedative hypnotics, tranquilizers, anticonvulsants, antihistamines (except non-sedating), benzodiazepines, clonidine or any medication known to affect dopamine at start of baseline period * significant unstable or uncontrolled medical/psychiatric disease * significant history of head trauma/surgery or seizure disorder * radiation exposure exceeding 20msv in last 12 months * pregnancy * substance abuse/dependence (including alcohol) * have sleep apnea, or are shift workers * on a sodium-restricted diet * has ever taken xyrem / sodium oxybate / ghb at any time * claustrophobia * metal implants / objects in the body that may interfere with mri * succinic semialdehyde dehydrogenase deficiency

Keywords: xyrem narcolepsy with cataplexy positron emission tomography dopamine
a novel virtual reality intervention for caregivers of people with dementia (virtualcare)

Conditions: Caregiver Burden

Summary: this clinical trial aims to explore if a virtual reality experience increases the beneficial effect of psychoeducational programs in informal caregivers of people with mild-to-moderate alzheimer's disease. this study will test changes in psychological distress and neural activity in brain systems that regulate stress and empathic care. participants will be randomized into two arms: the control group will participate in an online psychoeducational intervention, while the experimental group will participate in the psychoeducational intervention combined with virtual reality.


Eligibility criteria:
inclusion criteria: * being an unpaid informal caregiver (cg; i.e., family members or friends) living with or caring for a person with alzheimer's disease (ad) for at least 4 hours a day for at least six months before enrolment; * caring for a person with a diagnosis of ad at prodromal or mild stage (i.e., mini-mental state examination score:18-24) and still living at home. exclusion criteria: * receiving daily assistance for more than 10 hours from formal cgs; * being formal cgs (i.e., nurse or another paid figure); * being informal cgs of i) persons with moderate-to-severe ad, or ii) persons with non-ad diseases; * not having or being able to use a device connected to internet (e.g., smartphones or pc). * having received psychotherapeutic o psychological support, or having already participated to psychoeducational programs. * only a family member for person with dementia is accepted. exclusion criteria for experimental group (psychoeducation + vr): * medical history of epilepsy. exclusion criteria for subsample of caregivers assess with mri: * metal implants, artificial prostheses, pace-makers, prosthetic heart valves; * claustrophobia; * pregnancy.

Keywords: informal caregiver virtual reality psychoeducation intervention